DXNVX, JP Morgan Healthcare Partnering Meeting... Biotech Showcase Presentation

DXVX announced on the 26th that it will conduct partnering meetings on-site with companies participating in the '2024 JP Morgan Healthcare Conference' and 'Biotech Showcase 2024,' held in San Francisco, USA, from the 8th to the 10th of next month (local time). A presentation will be given at the Biotech Showcase.

The JP Morgan Healthcare Conference is the largest investment event in the global pharmaceutical and biotech industry. It is an event attended by investors, industry stakeholders, and companies from over 50 countries worldwide, hosted annually in January by the US investment bank JP Morgan. The Biotech Showcase is an investor conference held annually by the EBD Group, which organizes the world’s leading biotech partnering forum, and is held on a schedule similar to the JP Morgan Healthcare Conference each year. More than 3,200 biopharmaceutical professionals from around the world attend, with over 1,000 investors and more than 340 innovative biotech companies participating, resulting in over 6,000 one-on-one meetings, making it a large-scale event.

Continuing its push to enter the global stage, DXVX plans to participate for the first time in the major global conferences JP Morgan Conference and Biotech Showcase, following its attendance at CPHI World Wide Barcelona, to promote the company’s new drug development capabilities and the opening of new pipelines. At this event, DXVX will discuss various business cooperation plans, including discovering global partners for new drug development and supplying its products to overseas markets. In particular, at this year’s Biotech Showcase, DXVX will participate as a presenting company to explain its core business areas, including cancer vaccines, microbiome-based anticancer drugs, bacteria-based respiratory vaccines, companion diagnostic technologies and services, and genomic data analysis.

Additionally, DXVX will explain the R&D synergy with the Coree Group, including the cancer vaccine OVM-200, which is being acquired from Oxford Vacmedix, clinical trials at Policlinico Universitario Agostistino Gemelli, the comprehensive hospital of the Catholic University of Rome (Universit? Cattolica del Sacro Cuore) Medical School in Italy, and management through precision medical diagnostics and digital therapeutics related to metabolic diseases.

DXVX CEO Kwon Kyu-chan said, “During the event period in San Francisco, we will conduct presentations and partnering meetings at the Biotech Showcase for the first time since the company’s establishment, and we expect significant promotional effects for our company in the global market. Also, through one-on-one meetings with leading global pharmaceutical and biotech companies and investors participating in JP Morgan Healthcare, we plan to intensively discuss our R&D projects and accelerate the discovery of global partners.”